San Antonio, Texas, 78209, United States
NCT Number: NCT02411500
A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males
The primary objective of this study is to evaluate the pharmacokinetics of various TRV734 formulations in healthy male subjects.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy as determined by a responsible physician or trained qualified designee
- Males: 18 - 55 years inclusive at screening
- Capable of giving written informed consent
Exclusion criteria
- Clinically significant conditions or history of fainting or syncope
- Medical or psychiatric illness that could interfere with the completion of treatment and follow up
- Major surgery within 4-weeks of screening
- Known difficulty with obtaining intravenous access
- History of sensitivity to the study medication, or intolerance to opioids, or a history of medication or other allergy that contraindicates their participation
- Use of prescription or non-prescription medications
- History of excessive alcohol use
- History of drug abuse within 6 months of screening
- Use of any illegal drug within 30 days of screening and throughout participation in the study
- History of smoking or use of nicotine containing products within 3 months of screening and throughout participation in the study
- Donation of blood or plasma 4 weeks prior to dosing
- Participation in a clinical trial and has received medication within 30 days
- Weight <50 kg or BMI outside range of 18-32 kg/m2
- Positive for HIV antibody, hepatitis B virus surface antigen, or hepatitis C virus
- Unwillingness to abstain from sexual intercourse with a pregnant or lactating woman and, if engaging in sexual intercourse with a female partner of child-bearing potential, use a condom and spermicide, in addition to having their female partner use another form of contraception, and abstain from sperm donation
Treatment and study plan
TRV734
DrugSubjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
Primary outcomes
-
Evaluate the maximum observed plasma concentration (Cmax)
Time frame: 9-days
-
Evaluate the time at which the maximum plasma concentration was observed (tmax)
Time frame: 9-days
-
Evaluate the area under the plasma concentration-time curve from time 0 to the last measurable plasma concentration (AUC0-t)
Time frame: 9-days
-
Evaluate the area under the plasma concentration-time curve from time 0 to time extrapolated to infinity (AUC0-inf)
Time frame: 9-days
-
Evaluate the apparent elimination half-life (t1/2)
Time frame: 9-days
-
Evaluate the apparent clearance (CL/F)
Time frame: 9-days
Secondary outcomes
-
Safety and tolerability as measured by adverse events
Time frame: 9-days
-
Safety and tolerability as measured by clinical observations
Time frame: 9-days
-
Safety and tolerability as measured by 12-lead ECGs
Time frame: 9-days
-
Safety and tolerability as measured by cardiac telemetry monitoring
Time frame: 9-days
-
Safety and tolerability as measured by vital signs (BP, HR, RR and oral temperature)
Time frame: 9-days
-
Safety and tolerability as measured by oxygen saturation
Time frame: 9-days
-
Safety and tolerability as measured by safety laboratory tests
Time frame: 9-days
Sponsors and collaborators
Lead sponsor
Trevena Inc.
Industry
Registry information
Official study title
A Randomized, Open Label, Four Period, Cross-Over Study to Evaluate the Pharmacokinetics of Single Doses of Various TRV734 Formulations in Healthy Male Subjects
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Apr 8, 2015
- Registry last updated
- Nov 18, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details